Regulation of Glucose Transporters By Protein Kinases in Cancer Cells - European Medical Journal
×

Browse

Regulation of Glucose Transporters By Protein Kinases in Cancer Cells

|
3 Mins
Authors:
Andreia F.A. Henriques,1,2 Paulo Matos,1-3 *Peter Jordan1,2
Disclosure:

The authors have declared no conflicts of interest.

Acknowledgements:

This work was supported by the Fundação para a Ciência e Tecnologia through a centre grant (UID/MULTI/04046/2013) to BioISI.

Citation
EMJ Oncol. ;5[1]:50-52. Abstract Review No. AR9.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Receive our free quarterly newsletters and your choice of journal publication alerts, straight to your inbox.

Join our mailing list

Reprogramming of energy metabolism is one of the hallmarks of cancer, since tumour cells need to fuel their high proliferation rates.1 Warburg et al.2 first observed that cancer cells largely limit their method of energy production to glycolysis only. In order to compensate for lower ATP yields, cancer cells often upregulate expression of glucose transporters, typically GLUT1, which substantially increases extracellular glucose import into the cytoplasm.3

In normal physiology, insulin-responsive cells rapidly increase their glucose uptake 10–20-fold by translocating glucose transporter vesicles (specifically GLUT4) from intracellular storage compartments to the plasma membrane. In adipocytes, insulin activates the protein kinase AKT to phosphorylate the Rab GTPase activating protein, TBC1D4. This protein normally maintains Rab GTPases in their inactive state so that storage vesicles containing the glucose transporter remain cytoplasmic. Upon phosphorylation, TBC1D4 becomes inactive, allowing the translocation of GLUT vesicles so that more transporters are inserted into the plasma membrane.4 In muscle cells, the highly homologous Rab-GTPase activating protein TBC1D1 is predominantly expressed but also becomes phosphorylated by AKT in response to insulin.

Previous work from our laboratory described that the protein kinase WNK1 also participates in the regulation of TBC1D4. WNK1 forms a protein complex with TBC1D4 in human embryonic kidney (HEK293) cells and phosphorylates it in vitro. Phosphorylation by WNK1 was found to increase the binding of TBC1D4 to regulatory 14-3-3 proteins and to reduce its interaction with the exocytic small GTPase, Rab8A. This novel pathway regulates the cell surface expression of GLUT1 (Figure 1).5

Figure 1: The regulation of cell surface expression of GLUT1.
GLUT1: glucose transporter 1; PI3K: phosphoinositide 3-kinase.

The subfamily of WNK protein kinases belongs to the superfamily of 518 human protein kinase genes.6,7 WNK1 and WNK4 were shown to regulate the cell surface expression and activity of a variety of renal ion channels.7 The finding that WNK1 regulated GLUT1 showed, for the first time, that it is also involved in the cell surface expression of other plasma membrane transport proteins.5 Besides the catalytic domain, WNK1 contains coiled-coil domains, which, together with the large size of the protein, suggests that WNK1 also has scaffolding functions and may be involved in multiple cellular signalling processes.6-8 Interestingly, AKT can phosphorylate WNK1 at residue Thr60.9

Our goal was to characterise the role of protein kinase WNK1 in the phosphorylation network that regulates cellular glucose uptake in cancer cells. WNK1 expression was depleted by small interfering RNA in various colorectal cancer cell lines and key cell cycle proteins were analysed by a western blot in the presence of different glucose concentrations. WNK1-depleted cells showed higher apoptotic and cell cycle arrest phenotypes when cultured in low glucose medium.

In order to determine how WNK1 regulates GLUT1 translocation, key phosphorylation events were identified by mass spectrometry analysis, which revealed unique serine residues specifically phosphorylated by WNK1 in both TBC1D4 and the functionally related TBC1D1. The respective phosphomimetic mutants are currently being tested for their ability to modulate GLUT1 translocation. Together, these studies will contribute to an increased knowledge of the signalling pathways involved in the control of glucose uptake in cancer cells and will potentially allow the identification of novel therapeutic targets.

References
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144(5):646-74. Warburg O et al. The metabolism of tumors in the body. J Gen Physiol. 1927;8(6):519-30. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: A recipe for cancer growth. Genes Dev. 2009; 23(5):537-48. Zaid H et al. Insulin action on glucose transporters through molecular switches, tracks and tethers. Biochem J. 2008; 413(2):201-15. Mendes AI et al. Protein kinase WNK1 promotes cell surface expression of glucose transporter GLUT1 by regulating a Tre-2/ USP6-BUB2-Cdc16 domain family member 4 (TBC1D4)-Rab8A complex. J Biol Chem. 2010;285(50):39117-26. Veríssimo F, Jordan P. WNK kinases, a novel protein kinase subfamily in multi-cellular organisms. Oncogene. 2001; 20(39):5562-9. Kahle KT et al. Molecular physiology of the WNK kinases. Annu Rev Physiol. 2008;70:329-55. Xu BE et al. WNK1: Analysis of protein kinase structure, downstream targets, and potential roles in hypertension. Cell Res. 2005;15(1):6-10. Vitari AC et al. WNK1, the kinase mutated in an inherited high-blood-pressure syndrome, is a novel PKB (protein kinase B)/Akt substrate. Biochem J. 2004;378(Pt 1):257-68.